TG Therapeutics Has Quite The Promising Pipeline

Brean Capital assumed coverage of TG Therapeutics Inc TGTX with a Buy rating and $28 target price on promising pipeline.

The company has two lead oncology drug candidates in Phase III trials: TG-1101 (a monoclonal antibody that targets aunique epitope on the B-lymphocyte CD20 antigen) and TGR-1202 (a PI3K delta inhibitor).

"If approved, the company looks to package them as combination therapies at very competitive prices versus combination therapies from two different sources—especially important to payers for such treatments as lymphoma and other less aggressive cancers with prolonged treatment regimes," analyst Jason Wittes wrote in a note.

Meanwhile, TG has started testing TG-1101 in Multiple Sclerosis patients in a Phase II dose-finding trial in May. TG-1101 was also granted orphan status, in August, for the Treatment of Neuromyelitis Opticaand Neuromyelitis Optica Spectrum Disorder (NMO), a disease which is closely related to MS.

TG had cash of $75.8 million at the end of second quarter 2016 which management believes is sufficient to support operations into the second quarter of 2018.

At time of writing, shares of TG were up 0.60 percent to $8.43.